Effectiveness and safety of HRS-7535, a new oral drug that activates blood sugar control receptors, in people with type 2 diabetes not well managed by metformin and SGLT2 inhibitors: a multicenter, randomized, double-blind, placebo-controlled Phase II trial

HRS-7535, an oral small-molecule glucagon-like peptide-1 receptor agonist, is being evaluated for efficacy and safety in Chinese participants with type 2 diabetes.

• The study focuses on individuals with type 2 diabetes who are not adequately controlled by metformin and SGLT2 inhibitors.
• Efficacy and safety outcomes are being assessed for this new treatment approach.
• The research targets a specific population, indicating potential tailored therapies for diabetes management.

Simplified